Evommune, Inc. (EVMN)
NYSE:EVMN
EVMN Stock Chart & Stats
$23.56
--
Market closed
$23.56
--
Day’s Range― - ―
52-Week Range$13.89 - $33.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)935.27K
Market Cap
$918.83M
Enterprise Value$286.34M
Total Cash (Recent Filing)$149.20M
Total Debt (Recent Filing)$2.06M
Price to Earnings (P/E)―
Beta0.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,018,370
10 Day Avg. Volume412,591
30 Day Avg. Volume935,274
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue22.03
Enterprise Value/Gross Profit24.66
Enterprise Value/Ebitda-4.15
Forecast
1Y Price Target
$50.25Price Target Upside113.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA multi-year revenue increase from $5M to $13M demonstrates durable product traction and expanding commercial footprint. Sustained top-line growth provides a foundation to leverage gross margins, absorb R&D spend, and improve operating leverage as programs advance toward later‑stage trials and potential commercialization.
Recapitalized Balance SheetA dramatic reduction in leverage and a swing to positive equity materially lower solvency risk and give management strategic flexibility. This recapitalization reduces near‑term refinancing pressure and enables continued investment in clinical programs without immediate distress financing, supporting multi‑quarter program execution.
Positive PoC And Secured Near-Term FundingPositive Phase 2a proof‑of‑concept for EVO301 validates IL‑18 inhibition and de‑risks that program, supporting a move into Phase 2b and new indications. Coupled with a $125M private placement that extends runway, the company can advance mid‑stage trials and capture value from clinical milestones over the next 2–3 years.
Bears Say
Accelerating Cash BurnOperating and free cash flow have worsened materially year‑over‑year, rising to roughly -$76M in 2025. This persistent and accelerating burn increases reliance on external capital, compresses financial flexibility, and elevates execution risk if clinical timelines or revenue ramp slip over the medium term.
Large Persistent Net LossesSubstantial, recurring net losses show the cost base is far ahead of current revenue scale. Persistent operating deficits undermine margin sustainability and delay path to profitability, meaning long‑term value creation hinges on successful late‑stage development or significant revenue expansion.
Ongoing Funding DependenceEven after recapitalization, management notes the balance sheet's stability depends on continued funding discipline and reduced burn. This structural dependence implies future rounds or partnerships may be needed, risking dilution or strategic concessions that could constrain long‑term capital allocation and growth plans.
Evommune, Inc. News
EVMN FAQ
What was Evommune, Inc.’s price range in the past 12 months?
Evommune, Inc. lowest stock price was $13.88 and its highest was $33.20 in the past 12 months.
What is Evommune, Inc.’s market cap?
Evommune, Inc.’s market cap is $918.83M.
When is Evommune, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Evommune, Inc.’s earnings last quarter?
Currently, no data Available
Is Evommune, Inc. overvalued?
According to Wall Street analysts Evommune, Inc.’s price is currently Undervalued.
Does Evommune, Inc. pay dividends?
Evommune, Inc. does not currently pay dividends.
What is Evommune, Inc.’s EPS estimate?
Evommune, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evommune, Inc. have?
Evommune, Inc. has 36,018,370 shares outstanding.
What happened to Evommune, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evommune, Inc.?
Currently, no hedge funds are holding shares in EVMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evommune, Inc. Stock Smart Score
Company Description
Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
EVMN Stock 12 Month Forecast
Average Price Target
$50.25
▲(113.29% Upside)